$AMGN | Weekly TF | Breakout Territorytrend is your friend, find good risk to reward set-ups and play the trend
USE STOP LOSSES!!!!
AMGN trade ideas
$AMGN Technical and fundamental Breakout in AmgenEntry level $216 = Target price $237 = Stop loss $209
Bullish technical setup,
Fundamentally bullish with superb earnings and the announcement that they have taken a stake in BieGene, the wider the open the vault the better, start spending that cash hoard.
P/E ratio 16.36
Yield, 2.75%
Company profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Farmacéuticas al Alzathe pharmaceuticals are performing well so the market makers are currently buying on this sector, my principal list on this sector are AMGEN, PFIZER and BRISTOL MYERS, i'm waiting to break levels to buy
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (bliAMGN: Amgen
2019-09-24 16:00:00
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
AMGEN Inc AMGN stock looks attractive after a strong rallyAMGEN Inc AMGN american stock looks attractive after a strong rally, waiting for a pullback to weekly demand imbalance around $178 to buy the underlying stock.
We don't need any fundamental analysis on a stock to take a trading decision but if you are interested, Amgen AMGN has been a laggard. Amgen's slump had to do with the stocks slowing growth outlook combined with the ever present headwinds that the healthcare sector faces heading into an election year.However, Amgen could address its growth slump.
That's exactly what management did in August, causing the stock's price to spike. Yet, in the past five weeks Amgen shares have cooled off, giving investors who were previously experiencing fear of missing out the trade, the chance to get into the stock at a discount to recent highs.
Where is the place where those investors can plan to buy AMGEN again? Well, if you look at the attached weekly chart technical analysis, the whole movement started at $178 creating a very strong weekly demand level, that's where we can buy AMGEN inc again.
AMGN - Oct 18While the market and sector has been going up, AMGN has been selling off. Looking forward to AMGN finding support between 189 and 185. Good time to short if sell off continues.
AMGN down to $194 in 3 - 4 days, SHORTAMGN down to $194 in 3 - 4 days, SHORT.
Based on previous chart pattern, it looks like this is the setup. MACD is carousing over-down on daily. Every time this happened in the past we had a nice slide down in 3-4 days.
AMGN Defies DowntrendAMGN formed a tight short-term Symmetrical Triangle before running up on strong momentum, instigated by Professional Traders setting up for High Frequency Trader action. AMGN moved through technical resistance with ease.
AMGN attempting trend line breakout ahead of earningsAmgen is attempting a breakout above its one-month downward trend line this morning. I will wait to enter until I see a change in volume. Currently there's bearish divergence on the volume profile, which suggests that this may correct downward before confirming the breakout.
Amgen reports earnings tomorrow, and has a positive earnings surprise prediction from Zacks. Amgen has beaten analyst estimates 7 of 8 quarters in the last 2 years. The company's recent price weakness and great valuation (15.8% below the average analyst price target) makes it a good candidate for a pop on an earnings beat.
AMGN: This setting up for a nice move higher.I will be adding few
July 26th: 190 calls for the runup ONLY.
Daily AMGN forecast timing analysis by Supply-Demand strength21-Jun
Investing strategies by pretiming
Investing position about Supply-Demand(S&D) strength: In Rising section of high profit & low risk
Supply-Demand(S&D) strength Trend Analysis: In the midst of an upward trend of strong upward momentum price flow marked by the temporary falls and strong rises.
Today's S&D strength Flow: Supply-Demand strength has changed from a weak buying flow to a strengthening buying flow again.
View a Forecast Candlestick Shape Analysis of 10 days in the future: www.pretiming.com
(You can easily create a trading plan.)
D+1 Candlestick Color forecast: GREEN Candlestick
%D+1 Range forecast: 0.8% (HIGH) ~ 0.1% (LOW), 0.4% (CLOSE)
%AVG in case of rising: 1.2% (HIGH) ~ -0.6% (LOW), 0.8% (CLOSE)
%AVG in case of falling: 0.5% (HIGH) ~ -1.4% (LOW), -0.8% (CLOSE)
Price Forecast Timing Criteria: Price forecast timing is analyzed based on pretiming algorithm of Supply-Demand(S&D) strength.
AMGEN- Overbought, or Cup and handle?RSI is definitely overbought. This COULD lead to a PERFECTLY set up cup and handle right before earnings to pump this up. Earnings is on July 29. More than enough time to fill out the Cup, and form a handle for an explosive move up before earnings.
We are at the top BB so it could be a week or 2 before hitting the top to see if a handle forms, if AMGEN goes parabolic, or if this was a suckers rally.
This is purely speculation. I do not plan on trading this in the next 72 hours.
DYOR.
A very bullish short term Option trade in AmgenSomeone is expecting a very fruitful ending to the week in Amgen to place such a heavy bet on the stock reaching $190 by June 21st but the volume and bullish action this week makes it is very possible. We will be on watch for pre market moves tomorrow for a very quick trade.
AMGN daily double bottom and MACD divergenceAMGN has a small daily double bottom and MACD divergence so with the weekly chart still strong down this would be a short term trade. MACD seems to indicate price sb about $172, so bought some Jun 14th expiration 172.5 calls for 1.58. Probably hold for a few days max.
$AMGN A big week ahead for Amgen, now it's found a bottom. Amgen will present data from its oncology pipeline at the 55th Annual Meeting of the American Society of Clinical Oncology that begins on May 31. This Could a hugely significant day for NASDAQ:AMGN which is in need of some good news to reassure investors. They stock has been on a terrible run lately but it may now have found a bottom, ready to move higher as the entire sector sell-off has left these companies at very attractive P/E ratios, offering stability and cash generation at a time when tech is in the wars.
RECENT DEVELOPMENTS
Amgen (NASDAQ:AMGN) has made a cash offer of SEK 1,610 (US$167M) for Copenhagen-based Nuevolution AB, a developer of small molecule therapeutics in inflammation, oncology and immuno-oncology utilizing its drug discovery platform called Chemetics.
AVERAGE ANALYSTS PRICE TARGET $206
AVERAGE ANALYSTS RECOMMENDATION OVERWEIGHT
12 BUY
1 OVERWEIGHT
1 2 HOLD
P/E RATIO 13.66
COMPANY PROFILE
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA.
AMGN Fibonacci Retracement 4 hr chartI have opened a Jun 180 / May 187.50 Diagonal Spread.
I got in late on this. If it does not break through 180 in the next couple of pips then I will get out.
AMGN - Bear Flag Setup - 4 hr chartDid not break through fib retracement at 180. Possible Bear Flag setup. Will hold spreads for now. Out if it breaks under 177.
Amgen Ready for a ReboundOn a graphical level, a bullish divergence has formed between the price and the Commodity Channel Index (CCI). A close above the black trendline will give the entry signal (long) on Amgen.
First target area $ 179.65/182.47, while the stop loss below the last low ($ 168.44). I leave you free to decide the level on the basis of your money management.
$AMGN Good results might not be good enough. Cautious.Despite FDA approval for Amgen's new Enrel drug last week we see the bounce as the formation of a bear flag heading into earnings. Sentiment is so poor in the sector we fear that regardless of results the stock will eventually continue to drop. Amgen is very cheap at 14 P/E ratio with an average rating of HOLD among 25 analysts covering the name.
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate and Parsabiv.
